In this section, we provide information about the product's inventor, Dr Mark Babizhayey, and various academic papers he has submitted about efficacy and links to papers, firstly about specific canine use and secondly in humans.

The testing of various anti-glycation agents over nearly a decade led a Russian research team to the development of n-alpha-acetylcarnosine as a delivery system for the natural eye anti-oxidant of L-carnosine. Once laboratory testing was passed, the next stage began to test the N-acetyl-carnosine Can-C eye drops in the eyes of animals, (specifically canines and rabbits). These studies produced remarkably fast results in the improvement of clarity, glare sensitivity and overall vision for the animals involved. Furthermore, no serious side effects were noted and the beneficial effects were sustainable. Unsurprisingly, these positive results in animals led to the studies being continued in humans.

Control Study: Thirty dogs, (60 eyes) received topical application of Can-C 1% N-acetylcarnosine eye drop solution twice daily to cataracts.

•Improved visual behaviour of the animals within weeks of treatment.

•Cataract reversal starts from the periphery of the cataract followed by increased transparency of the lens.

•96% of canine eyes treated with N-acetylcarnosine (Can-C) showed notable improvements.

•Dogs with both immature and ripe cataracts showed significant visual improvement.

Current Drug Therapy, 2006, Vol. 1, No. 1 107 – Excerpt from; “TREATMENT OF AGE- RELATED CATARACTS IN CANINES” – Mark Babizhayev MA PhD:

“Controlled clinical trials for age-related cataracts in canines and rabbits has been conducted and the efficacy of using N-acetylcarnosine for cataract treatment was established. The striking results in canines and rabbits for both cataract reversal and prevention of lens opacities are clear.”

Many dog owners are now using this product to effectively address their pet’s cataract condition including veterinarians. Results in the Russian clinical trials were quite impressive with canines with no negative side affects. Dr. Babizhayev has also noted that Can-C appears to work even more effectively in canines than in humans. The dosage for animals has not yet been clearly defined so most pet owners are following the same dosage recommendation for humans and are applying 3 to 4 drops per affected eye daily. Remember also that the use of any unapproved drug for your animals should be discussed with your veterinarian. NOTE: Can-C™ is manufactured in a GMP certified, pharmaceutical facility which meets ISO 9001:2000 and ISO 13485:2003

In various small scale clinical trials, L-Carnosine has been shown to be highly effective at protecting against and/or reversing cataracts and loss of vision. A Asian trial on retirees showed L- Carnosine had a 100% effective / significant effect on primary senile cataracts, this dropping to only 80% on the most advanced cases.

The primary ingredient in Can-C™, the same effective formulation as Can-C™K9 is a proprietary form of N-Acetyl-Carnosine, a highly specific intraocular form of Carnosine which when applied topically to the eye, acts as both a stabilizer and time-release carrier for the di-peptide L-Carnosine, safely delivering it into the aqueous humour of the eye. Here, in the fluid area surrounding the lens, L-Carnosine becomes most active in its ability to act as a natural and highly effective free radical scavenger. L-Carnosine's most important cataract-inhibiting activity may be its capacity to compete with proteins for binding sites on sugar molecules, thereby preventing the production of advanced glycated end products (protein crosslinks). The inventor of Can-C, Dr. Mark Babizhayev, demonstrated in research studies that using non-approved n-acetyl carnosine formulations will not help treat senile cataract due to lack of anti-cataract antioxidant properties, hence why he developed the more effective proprietary solution Can-C™ and Can-C™K9.

The biological activity and therapeutic value of “carnosines” varies greatly depending on their source. For example, extractions from meat muscle components have minimal biological and antioxidant action due to impurities. Carnosine is difficult to purify chromatographically because it chelates divalent metal ions extensively making it difficult to retain its biological and antioxidant activities. Whereas the patented Can-C™ N-acetylcarnosine eye drops from Profound Products (Innovative Vision t/a IVP), in collaboration with their Japanese partner who spent years researching to identify a specific purity level of N-acetyl-carnosine (NAC) that that would ensure both safety and optimal results) can be safely applied to your eyes or those of your beloved dog. They have discovered, developed and patented a highly purified form of n-acetyl carnosine, which has excellent biological activity and has been proven effective in controlled human lens studies. In lower doses it is also considered safe in canines.

Note: After 6 months optimal N-Acetyl-Carnosine levels have been re-established in the eyes at which time a reduction to half the recommended amount provides ongoing support for continued vision improvement at half the cost!

Curious about the FDA's approval process and its impact on canine health solutions? Head over to our dedicated page where we delve into the intricacies of FDA approval and its relevance to alternative health solutions for dogs. We believe in transparency and aim to provide you with the information you need to make informed decisions about your pet's well-being.